目的:探讨布地奈德雾化吸入治疗急性会厌炎的临床疗效.方法:将54例急性会厌炎患者随机分为观察组(26例)和对照组(28例).所有患者均给予抗生素、激素、吸氧、补充水电解质等常规综合治疗.观察组在常规治疗的基础上给予布地奈德治疗.两组连续治疗7 d后进行疗效比较.结果:观察组25例中治愈14例,治愈率为53.8%;对照组28例中治愈15例,治愈率为53.6%.两组治愈率比较,差异无统计学意义(P>0.05).观察组不良反应发生率为30.8%,对照组为60.7%.两组不良反应发生率相比,差异有统计学意义(x2=4.86,P<0.05).结论:布地奈德雾化吸入辅助治疗急性会厌炎全身副作用小,临床疗效满意,可于临床推广应用.%Objective: To study the clinical efficacy of Budesonide atomization inhalation in the treatment of acute epiglottis. Methods: 54 cases of patients with acute epiglottis were randomly divided into observation group (26 cases) and control group (28 cases). All patients were given comprehensive treatment such as antibiotics, hormone, oxygen. The observation group was given Budesonide on the basis of conventional treatment. After 7 days, the therapeutic efficacy of two groups was compared. Results: The observation group in 25 patients cured in 14 cases, cure percentage reached 53.8％, 28 cases of control group in 15 cases, the cure rate for 53.6％. Two groups of cure rate was no significance difference (ρ＞0.05). In the observation group, the incidence of adverse was 30.8％, and was 60.7％ in the control group. The observation group adverse reaction rate compared with control group was significant difference (χ2=4.86, ρ＜0.05). Conclusion: Budesonide atomization inhalation in the adjuvant treatment of acute epiglottis has small systemic side effects, well clinical curative effect, and can be satisfied in clinical application.
展开▼
